ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and fatal malignancy, although gemcitabine is administered as a single or combined therapeutic agent. Our previous study demonstrated that ANP32E overexpression promoted PDAC cell proliferation. However, whether it affects treat...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Molecular and Cellular Probes |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0890850825000234 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849720330489167872 |
|---|---|
| author | Xiaohong Liu Yelin Zhao Li Zhang Junting Wang Liaoxin Luo Shihui Zhang Qin Zhu Yuchen Shi Chenyu Yuan Qifeng Xiao Mengran Xiong Yuanyuan Duan Hebing Chen Hongjuan Yao Lin Cai Jianwei Zhang Guangxi Li Liang Li |
| author_facet | Xiaohong Liu Yelin Zhao Li Zhang Junting Wang Liaoxin Luo Shihui Zhang Qin Zhu Yuchen Shi Chenyu Yuan Qifeng Xiao Mengran Xiong Yuanyuan Duan Hebing Chen Hongjuan Yao Lin Cai Jianwei Zhang Guangxi Li Liang Li |
| author_sort | Xiaohong Liu |
| collection | DOAJ |
| description | Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and fatal malignancy, although gemcitabine is administered as a single or combined therapeutic agent. Our previous study demonstrated that ANP32E overexpression promoted PDAC cell proliferation. However, whether it affects treatment outcome and clinical prognosis is still unclear. In the present study, we aimed to determine whether ANP32E is negatively associated with the treatment outcome of gemcitabine. Methods: We collected clinical characteristics and treatment information from a total of 75 PDAC patients to assess the association of ANP32E expression via immunohistochemical (IHC) staining with overall survival (OS) in patients who were or were not treated with gemcitabine-based chemotherapy, followed by a clinical replication study with transcriptomic data from the TCGA database and functional validation experiments involving the knockdown of ANP32E in the Hup-T3 and SU86.86 human pancreatic cancer cell lines. Results: We demonstrated the interference effect of ANP32E on gemcitabine efficacy and patient prognosis in PDAC patients by using our own clinical samples or publicly available TCGA datasets. Downregulation of ANP32E significantly sensitized Hup-T3 and SU86.86 cells to gemcitabine, which was consistent with the results of the above association studies. Conclusion: Our findings suggest that ANP32E might serve as a negative biomarker for poor prognosis and a predictive indicator for poor gemcitabine efficacy. These findings suggest that ANP32E might be a potential therapeutic target to help develop effective drugs to overcome gemcitabine resistance and reduce the risk for relapse or metastasis in patients with PDAC. |
| format | Article |
| id | doaj-art-942a8329b1944725aaa87bb99dec8dd0 |
| institution | DOAJ |
| issn | 0890-8508 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Molecular and Cellular Probes |
| spelling | doaj-art-942a8329b1944725aaa87bb99dec8dd02025-08-20T03:11:57ZengElsevierMolecular and Cellular Probes0890-85082025-08-018210203010.1016/j.mcp.2025.102030ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosisXiaohong Liu0Yelin Zhao1Li Zhang2Junting Wang3Liaoxin Luo4Shihui Zhang5Qin Zhu6Yuchen Shi7Chenyu Yuan8Qifeng Xiao9Mengran Xiong10Yuanyuan Duan11Hebing Chen12Hongjuan Yao13Lin Cai14Jianwei Zhang15Guangxi Li16Liang Li17State Key Laboratory of Respiratory Health and Multimorbidity, NHC Key Laboratory of Biotechnology for Microbial Drugs, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, NO.1 Tiantan Xili, Beijing, 100050, China; Qilu Hospital of Shandong University, Jinan, 250012, Shandong Province, China; Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, 100053, ChinaState Key Laboratory of Respiratory Health and Multimorbidity, NHC Key Laboratory of Biotechnology for Microbial Drugs, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, NO.1 Tiantan Xili, Beijing, 100050, ChinaState Key Laboratory of Respiratory Health and Multimorbidity, NHC Key Laboratory of Biotechnology for Microbial Drugs, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, NO.1 Tiantan Xili, Beijing, 100050, ChinaInstitute of Health Service and Transfusion Medicine, Beijing, 100850, ChinaDepartment of Biopharmaceuticals, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, ChinaDepartment of Biopharmaceuticals, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, ChinaDepartment of Biopharmaceuticals, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, ChinaDongzhimen Hospital, Beijing University of Chinese Medicine, No.5 Haiyuncang, Beijing, 100700, ChinaState Key Laboratory of Respiratory Health and Multimorbidity, NHC Key Laboratory of Biotechnology for Microbial Drugs, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, NO.1 Tiantan Xili, Beijing, 100050, ChinaPancreatic and Gastric Surgery Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, ChinaGuang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, 100053, ChinaGuang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, 100053, ChinaInstitute of Health Service and Transfusion Medicine, Beijing, 100850, ChinaState Key Laboratory of Respiratory Health and Multimorbidity, NHC Key Laboratory of Biotechnology for Microbial Drugs, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, NO.1 Tiantan Xili, Beijing, 100050, ChinaDepartment of Biopharmaceuticals, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang Province, China; Co-corresponding authors.Pancreatic and Gastric Surgery Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China; Co-corresponding authors. Pancreatic and Gastric Surgery Department, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, ChinaGuang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, Beijing, 100053, China; Co-corresponding authors. Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences, No.5 BeiXianGe St., Beijing 100053, ChinaState Key Laboratory of Respiratory Health and Multimorbidity, NHC Key Laboratory of Biotechnology for Microbial Drugs, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, NO.1 Tiantan Xili, Beijing, 100050, China; Co-corresponding authors. State Key Laboratory of Respiratory Health and Multimorbidity, NHC Key Laboratory of Antibiotic Bioengineering of National Health and Family Planning Commission, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, NO.1 Tiantan Xili, Beijing, 100050, China.Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and fatal malignancy, although gemcitabine is administered as a single or combined therapeutic agent. Our previous study demonstrated that ANP32E overexpression promoted PDAC cell proliferation. However, whether it affects treatment outcome and clinical prognosis is still unclear. In the present study, we aimed to determine whether ANP32E is negatively associated with the treatment outcome of gemcitabine. Methods: We collected clinical characteristics and treatment information from a total of 75 PDAC patients to assess the association of ANP32E expression via immunohistochemical (IHC) staining with overall survival (OS) in patients who were or were not treated with gemcitabine-based chemotherapy, followed by a clinical replication study with transcriptomic data from the TCGA database and functional validation experiments involving the knockdown of ANP32E in the Hup-T3 and SU86.86 human pancreatic cancer cell lines. Results: We demonstrated the interference effect of ANP32E on gemcitabine efficacy and patient prognosis in PDAC patients by using our own clinical samples or publicly available TCGA datasets. Downregulation of ANP32E significantly sensitized Hup-T3 and SU86.86 cells to gemcitabine, which was consistent with the results of the above association studies. Conclusion: Our findings suggest that ANP32E might serve as a negative biomarker for poor prognosis and a predictive indicator for poor gemcitabine efficacy. These findings suggest that ANP32E might be a potential therapeutic target to help develop effective drugs to overcome gemcitabine resistance and reduce the risk for relapse or metastasis in patients with PDAC.http://www.sciencedirect.com/science/article/pii/S0890850825000234Pancreatic ductal adenocarcinomaANP32EPrognosis biomarkerGemcitabine resistance |
| spellingShingle | Xiaohong Liu Yelin Zhao Li Zhang Junting Wang Liaoxin Luo Shihui Zhang Qin Zhu Yuchen Shi Chenyu Yuan Qifeng Xiao Mengran Xiong Yuanyuan Duan Hebing Chen Hongjuan Yao Lin Cai Jianwei Zhang Guangxi Li Liang Li ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis Molecular and Cellular Probes Pancreatic ductal adenocarcinoma ANP32E Prognosis biomarker Gemcitabine resistance |
| title | ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis |
| title_full | ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis |
| title_fullStr | ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis |
| title_full_unstemmed | ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis |
| title_short | ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis |
| title_sort | anp32e expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis |
| topic | Pancreatic ductal adenocarcinoma ANP32E Prognosis biomarker Gemcitabine resistance |
| url | http://www.sciencedirect.com/science/article/pii/S0890850825000234 |
| work_keys_str_mv | AT xiaohongliu anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT yelinzhao anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT lizhang anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT juntingwang anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT liaoxinluo anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT shihuizhang anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT qinzhu anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT yuchenshi anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT chenyuyuan anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT qifengxiao anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT mengranxiong anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT yuanyuanduan anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT hebingchen anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT hongjuanyao anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT lincai anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT jianweizhang anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT guangxili anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis AT liangli anp32eexpressioninpancreaticcancerisassociatedwithimpairedgemcitabineefficacyandpoorpatientprognosis |